Spravato vs Generic Ketamine: The Difference Matters

Spravato and ketamine are related compounds used for overlapping reasons, and they are not interchangeable. One is an FDA-approved medicine with a mandatory supervision programme attached to it. The other is an old anaesthetic being used off-label. A great deal of marketing depends on you not noticing the difference.

Start with the chemistry, because everything else follows from it. Ketamine as manufactured is a racemic mixture: equal parts of two mirror-image molecules, S-ketamine (esketamine) and R-ketamine. Spravato is the S-enantiomer isolated and formulated as a nasal spray. Esketamine is therefore a component of ketamine rather than a different drug — but it was developed, trialled and licensed as its own product, and that is what separates them in every way that matters to a patient.

Regulatory status: the distinction that gets blurred

Spravato was approved by the FDA in 2019 for adults with treatment-resistant depression, used together with an oral antidepressant. A further indication followed for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behaviour. That approval rests on a trial programme reviewed by the agency and carries an approved label describing the population, the dosing and the risks.

Racemic ketamine has no FDA approval for depression. It is approved as an anaesthetic. When a clinician prescribes it for depression, they are prescribing off-label.

Off-label prescribing is legal, ethical and routine; much of paediatric and psychiatric practice would be impossible without it. It means the FDA has not evaluated the drug for that use, not that the use is improper. But there is a real difference between "a regulator reviewed the evidence and approved this indication" and "a clinician judged this reasonable based on the published literature." Any clinic that describes off-label ketamine as FDA-approved, or lets you leave with that impression, has told you something about how it operates.

How each one is actually given

Spravato

Spravato is a nasal spray that you operate, under direct observation, in the clinic. A healthcare professional watches you take it, and you then stay for a monitoring period — a couple of hours is typical — during which blood pressure is checked and you are observed for sedation and dissociation. You cannot drive afterwards. The device never leaves the certified setting.

This is not the clinic being cautious. It is a legal requirement of the REMS — Risk Evaluation and Mitigation Strategy — that the FDA attached to the approval. REMS programmes are imposed on a small number of drugs where the agency judges that specific safeguards are needed for the benefits to outweigh the risks. Under the Spravato REMS, the healthcare setting and the pharmacy must be certified, the patient must be enrolled, and the monitoring must be documented. A provider offering Spravato outside that structure is not offering Spravato.

Dosing typically runs twice weekly at first, then reduces in frequency, always alongside a daily oral antidepressant. It is a course of appointments, not a prescription you collect.

Racemic ketamine

Off-label ketamine is used in several forms, and they are not equivalent to each other either.

Intravenous infusion in a clinic is the form with the longest research history in depression. It involves a slow infusion, usually around forty minutes, with monitoring of blood pressure, heart rate and level of consciousness, and an observation period afterwards. This is the setting most of the published depression literature describes.

Intramuscular injection is also given in clinics. Faster to deliver, less easily adjusted mid-dose than an infusion.

Sublingual lozenges or troches are the form used by most at-home telehealth programmes. Absorption by this route is lower and considerably more variable between people than intravenous dosing, there is much less controlled evidence behind it, and the setting removes the monitoring the infusion model depends on. That combination is why the at-home model has drawn regulatory and professional attention. What adequate screening and monitoring should look like is set out in the piece on at-home ketamine safety.

Monitoring, and why it exists

Both drugs raise blood pressure and heart rate, sometimes substantially, after dosing. Both produce dissociation — a sense of detachment from your body or surroundings that can be disorienting and occasionally frightening. Both cause sedation, and the impairment outlasts the obvious effects, which is why driving is off the table for the rest of the day.

Monitoring is how those effects are caught and managed: a blood pressure reading before and after, someone in the building who can respond if the reading is high or the dissociation becomes distressing, a period where you are not alone. None of it is theatre, and its absence is the clearest signal that a programme is cutting corners.

Who gets screened out

Eligibility for either treatment is a clinical decision made after assessment, and a meaningful number of people who want it are told no. The considerations overlap:

• Psychosis or a psychotic disorder, personal or in some cases family history. Both drugs can produce dissociative and perceptual effects, and that is a poor combination with an underlying psychotic illness.
• Cardiovascular conditions — uncontrolled hypertension, a history of aneurysm or arteriovenous malformation, recent cardiovascular events. The blood pressure rise is the problem.
• A history of substance misuse, ketamine in particular, but also more broadly. Ketamine has genuine misuse potential.
• Pregnancy, and pregnancy planning is part of the conversation.
• Certain liver conditions, and some drug interactions, depending on the case.

A screening conversation that does not cover these is not a screening conversation. This is one of the areas where the difference between a clinical practice and a sales funnel is easiest to see — the warning signs are set out in how to spot a prescription mill.

Insurance and cost

This is where the regulatory distinction becomes practical. Because Spravato is FDA-approved for a defined indication, insurance can cover it, and many plans do — usually with prior authorisation requiring documentation of the failed antidepressant trials. Administration and monitoring time are billed separately.

Off-label ketamine is generally not covered. Patients typically pay out of pocket, and prices vary widely with no obvious relationship to the quality of the clinical care. Some costs may be HSA or FSA eligible when the treatment is for a medical purpose; our overview of the rules is a starting point rather than tax advice.

Why the two get conflated

Partly because it is genuinely confusing. Esketamine is ketamine in a chemical sense, so "ketamine is FDA-approved for depression" can be constructed to sound defensible while being materially misleading. And partly because "FDA-approved" is the most valuable phrase in health marketing. A page that mentions FDA approval in one paragraph and its own off-label product in the next, without saying which is which, is doing that on purpose.

The test is simple. Ask a provider directly: is what you are offering me FDA-approved for depression, or is it off-label? The answer is one word and there is no reason for it to be evasive.

What to ask before you commit

Is this esketamine under the REMS programme, or off-label racemic ketamine? Who is prescribing, and in which states are they licensed? What screening happens before a decision, and what would rule me out? What monitoring happens during and after dosing? Who do I call at 9pm? Is the fee charged regardless of whether I am accepted?

That last one matters more than it looks. A fee contingent on approval gives the person making the clinical decision a stake in one answer.

For the wider picture, start with our full guide to ketamine for treatment-resistant depression, or read what our own ketamine therapy service assesses for. Common questions are on the FAQ page.